MTCYBP16

Across TCGA pan-cancer cohorts, MTCYBP16 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated MTCYBP16 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MTCYBP16 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MTCYBP16 expression acts as an unfavorable survival marker, although some lineages such as BLCA and LUSC show a favorable association.

BLCA, LUSC, and ACC are the cancer types where MTCYBP16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.634	0.453	<.001	164	view →
LUSC	OS	Tertile	All	0.495	0.365	.003	71	view →
ACC	DFS	Median	All	0.766	0.416	<.001	68	view →
LUAD	DFS	Tertile	IV	0.342	0.893	<.001	55	view →
UCS	DFS	Tertile	All	0.110	0.339	.017	40	view →
KIRP	DFS	Tertile	II,III,IV	0.789	0.380	.003	33	view →
SKCM	OS	Tertile	III,IV	0.688	0.268	.012	19	view →
PAAD	DFS	Tertile	III,IV	0.275	0.794	.008	15	view →
ESCA	OS	Tertile	IV	0.713	0.264	.024	9	view →
KIRC	DFS	Tertile	III,IV	0.756	0.574	.016	8	view →
UCEC	DFS	Median	II,III,IV	0.680	0.288	.028	8	view →
KICH	OS	Quartile	II,III,IV	1.000	0.602	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

MTCYBP16–BLCA (DFS)

Open the BLCA breakdown →